|
|
Vaccine Detail
|
IDO peptide vaccine |
| Vaccine Information |
- Vaccine Name: IDO peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: IDO peptide (immunomodulatory enzyme indoleamine 2,3-dioxygenase) (NCT02077114; NCIT_C159498)
- Immunization Route: Other
- Description: This is a peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. (NCIT_C159498) This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized. (NCT02077114)
|
| Host Response |
|
|
| References |
NCIT_C159498: IDO Peptide Vaccine IO102 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498]
NCT02077114: Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma [https://clinicaltrials.gov/study/NCT02077114]
|
|
